Intrinsic value of Amarin ADR - AMRN

Previous Close

$3.02

  Intrinsic Value

$1.52

stock screener

  Rating & Target

sell

-50%

Previous close

$3.02

 
Intrinsic value

$1.52

 
Up/down potential

-50%

 
Rating

sell

We calculate the intrinsic value of AMRN stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 2017), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 0.8

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2018
   2019
   2020
   2021
   2022
   2023
   2024
   2025
   2026
   2027
   2028
   2029
   2030
   2031
   2032
   2033
   2034
   2035
   2036
   2037
   2038
   2039
   2040
   2041
   2042
   2043
   2044
   2045
   2046
   2047

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  39.20
  35.78
  32.70
  29.93
  27.44
  25.19
  23.18
  21.36
  19.72
  18.25
  16.92
  15.73
  14.66
  13.69
  12.82
  12.04
  11.34
  10.70
  10.13
  9.62
  9.16
  8.74
  8.37
  8.03
  7.73
  7.46
  7.21
  6.99
  6.79
  6.61
Revenue, $m
  252
  342
  454
  590
  752
  941
  1,159
  1,407
  1,684
  1,992
  2,329
  2,695
  3,090
  3,513
  3,964
  4,441
  4,945
  5,474
  6,028
  6,608
  7,214
  7,844
  8,501
  9,183
  9,893
  10,630
  11,397
  12,193
  13,021
  13,882
Variable operating expenses, $m
  153
  207
  274
  356
  454
  568
  699
  848
  1,016
  1,201
  1,403
  1,624
  1,862
  2,117
  2,388
  2,676
  2,979
  3,298
  3,633
  3,982
  4,347
  4,727
  5,122
  5,534
  5,961
  6,406
  6,868
  7,347
  7,846
  8,365
Fixed operating expenses, $m
  123
  125
  128
  131
  134
  137
  140
  143
  146
  149
  152
  156
  159
  163
  166
  170
  174
  178
  181
  185
  190
  194
  198
  202
  207
  211
  216
  221
  226
  231
Total operating expenses, $m
  276
  332
  402
  487
  588
  705
  839
  991
  1,162
  1,350
  1,555
  1,780
  2,021
  2,280
  2,554
  2,846
  3,153
  3,476
  3,814
  4,167
  4,537
  4,921
  5,320
  5,736
  6,168
  6,617
  7,084
  7,568
  8,072
  8,596
Operating income, $m
  -23
  10
  52
  103
  164
  236
  320
  415
  523
  642
  773
  915
  1,069
  1,233
  1,409
  1,595
  1,791
  1,998
  2,214
  2,441
  2,677
  2,924
  3,180
  3,447
  3,725
  4,013
  4,313
  4,625
  4,949
  5,287
EBITDA, $m
  -21
  12
  54
  106
  168
  242
  326
  423
  531
  652
  784
  928
  1,083
  1,250
  1,428
  1,616
  1,815
  2,024
  2,243
  2,472
  2,711
  2,961
  3,220
  3,490
  3,771
  4,063
  4,367
  4,683
  5,011
  5,352
Interest expense (income), $m
  17
  10
  8
  14
  21
  30
  41
  53
  68
  84
  102
  123
  145
  169
  195
  223
  252
  284
  317
  352
  388
  427
  466
  508
  551
  596
  643
  691
  742
  794
  849
Earnings before tax, $m
  -33
  2
  38
  81
  134
  196
  267
  348
  438
  539
  650
  770
  900
  1,039
  1,186
  1,343
  1,507
  1,681
  1,863
  2,053
  2,251
  2,457
  2,672
  2,896
  3,129
  3,371
  3,622
  3,883
  4,155
  4,438
Tax expense, $m
  0
  0
  10
  22
  36
  53
  72
  94
  118
  146
  176
  208
  243
  280
  320
  362
  407
  454
  503
  554
  608
  663
  722
  782
  845
  910
  978
  1,049
  1,122
  1,198
Net income, $m
  -33
  1
  27
  59
  98
  143
  195
  254
  320
  394
  475
  562
  657
  758
  866
  980
  1,100
  1,227
  1,360
  1,498
  1,643
  1,794
  1,951
  2,114
  2,284
  2,461
  2,644
  2,835
  3,033
  3,240

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  225
  305
  405
  526
  671
  840
  1,034
  1,255
  1,502
  1,777
  2,077
  2,404
  2,757
  3,134
  3,536
  3,962
  4,411
  4,883
  5,378
  5,895
  6,435
  6,997
  7,583
  8,192
  8,825
  9,483
  10,167
  10,877
  11,616
  12,384
Adjusted assets (=assets-cash), $m
  225
  305
  405
  526
  671
  840
  1,034
  1,255
  1,502
  1,777
  2,077
  2,404
  2,757
  3,134
  3,536
  3,962
  4,411
  4,883
  5,378
  5,895
  6,435
  6,997
  7,583
  8,192
  8,825
  9,483
  10,167
  10,877
  11,616
  12,384
Revenue / Adjusted assets
  1.120
  1.121
  1.121
  1.122
  1.121
  1.120
  1.121
  1.121
  1.121
  1.121
  1.121
  1.121
  1.121
  1.121
  1.121
  1.121
  1.121
  1.121
  1.121
  1.121
  1.121
  1.121
  1.121
  1.121
  1.121
  1.121
  1.121
  1.121
  1.121
  1.121
Average production assets, $m
  12
  16
  21
  28
  35
  44
  54
  66
  79
  94
  109
  127
  145
  165
  186
  209
  232
  257
  283
  311
  339
  369
  400
  432
  465
  500
  536
  573
  612
  652
Working capital, $m
  7
  10
  13
  17
  21
  26
  32
  39
  47
  56
  65
  75
  87
  98
  111
  124
  138
  153
  169
  185
  202
  220
  238
  257
  277
  298
  319
  341
  365
  389
Total debt, $m
  98
  171
  261
  370
  500
  652
  827
  1,025
  1,248
  1,495
  1,766
  2,060
  2,377
  2,717
  3,078
  3,462
  3,866
  4,291
  4,736
  5,202
  5,687
  6,194
  6,721
  7,269
  7,839
  8,431
  9,046
  9,686
  10,350
  11,041
Total liabilities, $m
  202
  275
  364
  474
  604
  756
  931
  1,129
  1,352
  1,599
  1,870
  2,164
  2,481
  2,821
  3,182
  3,565
  3,970
  4,395
  4,840
  5,306
  5,791
  6,298
  6,825
  7,373
  7,943
  8,535
  9,150
  9,790
  10,454
  11,145
Total equity, $m
  22
  31
  40
  53
  67
  84
  103
  125
  150
  178
  208
  240
  276
  313
  354
  396
  441
  488
  538
  590
  643
  700
  758
  819
  883
  948
  1,017
  1,088
  1,162
  1,238
Total liabilities and equity, $m
  224
  306
  404
  527
  671
  840
  1,034
  1,254
  1,502
  1,777
  2,078
  2,404
  2,757
  3,134
  3,536
  3,961
  4,411
  4,883
  5,378
  5,896
  6,434
  6,998
  7,583
  8,192
  8,826
  9,483
  10,167
  10,878
  11,616
  12,383
Debt-to-equity ratio
  4.380
  5.590
  6.430
  7.020
  7.450
  7.760
  7.990
  8.170
  8.310
  8.410
  8.500
  8.570
  8.620
  8.670
  8.710
  8.740
  8.760
  8.790
  8.810
  8.820
  8.840
  8.850
  8.860
  8.870
  8.880
  8.890
  8.900
  8.900
  8.910
  8.920
Adjusted equity ratio
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -33
  1
  27
  59
  98
  143
  195
  254
  320
  394
  475
  562
  657
  758
  866
  980
  1,100
  1,227
  1,360
  1,498
  1,643
  1,794
  1,951
  2,114
  2,284
  2,461
  2,644
  2,835
  3,033
  3,240
Depreciation, amort., depletion, $m
  2
  2
  3
  4
  4
  5
  6
  7
  9
  10
  11
  13
  15
  17
  19
  21
  23
  26
  28
  31
  34
  37
  40
  43
  46
  50
  54
  57
  61
  65
Funds from operations, $m
  -31
  4
  30
  63
  102
  148
  201
  261
  329
  404
  486
  575
  671
  775
  885
  1,001
  1,124
  1,253
  1,388
  1,529
  1,677
  1,831
  1,991
  2,157
  2,331
  2,511
  2,698
  2,892
  3,094
  3,305
Change in working capital, $m
  2
  3
  3
  4
  5
  5
  6
  7
  8
  9
  9
  10
  11
  12
  13
  13
  14
  15
  16
  16
  17
  18
  18
  19
  20
  21
  21
  22
  23
  24
Cash from operations, $m
  -33
  1
  27
  59
  98
  143
  195
  254
  321
  395
  476
  565
  660
  763
  872
  988
  1,110
  1,238
  1,372
  1,513
  1,660
  1,813
  1,972
  2,138
  2,311
  2,490
  2,676
  2,870
  3,071
  3,281
Maintenance CAPEX, $m
  -1
  -1
  -2
  -2
  -3
  -4
  -4
  -5
  -7
  -8
  -9
  -11
  -13
  -15
  -17
  -19
  -21
  -23
  -26
  -28
  -31
  -34
  -37
  -40
  -43
  -46
  -50
  -54
  -57
  -61
New CAPEX, $m
  -3
  -4
  -5
  -6
  -8
  -9
  -10
  -12
  -13
  -14
  -16
  -17
  -19
  -20
  -21
  -22
  -24
  -25
  -26
  -27
  -28
  -30
  -31
  -32
  -33
  -35
  -36
  -37
  -39
  -40
Cash from investing activities, $m
  -4
  -5
  -7
  -8
  -11
  -13
  -14
  -17
  -20
  -22
  -25
  -28
  -32
  -35
  -38
  -41
  -45
  -48
  -52
  -55
  -59
  -64
  -68
  -72
  -76
  -81
  -86
  -91
  -96
  -101
Free cash flow, $m
  -38
  -4
  20
  51
  87
  130
  180
  237
  301
  373
  451
  537
  629
  728
  834
  947
  1,065
  1,190
  1,321
  1,458
  1,601
  1,750
  1,905
  2,066
  2,234
  2,409
  2,590
  2,779
  2,975
  3,179
Issuance/(repayment) of debt, $m
  -24
  72
  90
  109
  130
  152
  175
  199
  223
  247
  271
  294
  317
  340
  362
  383
  404
  425
  445
  466
  486
  506
  527
  548
  570
  592
  615
  639
  665
  691
Issuance/(repurchase) of shares, $m
  121
  7
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash from financing (excl. dividends), $m  
  97
  79
  90
  109
  130
  152
  175
  199
  223
  247
  271
  294
  317
  340
  362
  383
  404
  425
  445
  466
  486
  506
  527
  548
  570
  592
  615
  639
  665
  691
Total cash flow (excl. dividends), $m
  59
  75
  110
  160
  217
  282
  355
  436
  524
  620
  722
  831
  946
  1,068
  1,196
  1,330
  1,469
  1,615
  1,766
  1,923
  2,086
  2,256
  2,432
  2,614
  2,804
  3,001
  3,206
  3,418
  3,640
  3,870
Retained Cash Flow (-), $m
  -121
  -8
  -10
  -12
  -14
  -17
  -19
  -22
  -25
  -27
  -30
  -33
  -35
  -38
  -40
  -43
  -45
  -47
  -49
  -52
  -54
  -56
  -59
  -61
  -63
  -66
  -68
  -71
  -74
  -77
Prev. year cash balance distribution, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  14
  19
  26
  35
  45
  58
  72
  89
  108
  130
  153
  179
  208
  238
  271
  305
  342
  381
  421
  464
  509
  555
  604
  655
  707
  762
  819
  878
  939
  1,003
Cash available for distribution, $m
  -62
  67
  100
  148
  203
  265
  336
  414
  499
  592
  692
  798
  911
  1,030
  1,156
  1,287
  1,424
  1,568
  1,716
  1,871
  2,032
  2,200
  2,373
  2,553
  2,741
  2,935
  3,137
  3,347
  3,566
  3,793
Discount rate, %
  13.50
  14.18
  14.88
  15.63
  16.41
  17.23
  18.09
  19.00
  19.95
  20.94
  21.99
  23.09
  24.24
  25.46
  26.73
  28.07
  29.47
  30.94
  32.49
  34.11
  35.82
  37.61
  39.49
  41.47
  43.54
  45.72
  48.00
  50.40
  52.92
  55.57
PV of cash for distribution, $m
  -55
  51
  66
  83
  95
  102
  105
  103
  97
  88
  78
  66
  54
  43
  33
  25
  18
  12
  8
  5
  3
  2
  1
  1
  0
  0
  0
  0
  0
  0
Current shareholders' claim on cash, %
  50.0
  38.4
  38.4
  38.4
  38.4
  38.4
  38.4
  38.4
  38.4
  38.4
  38.4
  38.4
  38.4
  38.4
  38.4
  38.4
  38.4
  38.4
  38.4
  38.4
  38.4
  38.4
  38.4
  38.4
  38.4
  38.4
  38.4
  38.4
  38.4
  38.4

Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company operates through the development and commercialization of Vascepa segment. The Company's lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.

FINANCIAL RATIOS  of  Amarin ADR (AMRN)

Valuation Ratios
P/E Ratio -9.5
Price to Sales 6.3
Price to Book -90.4
Price to Tangible Book
Price to Cash Flow -11.3
Price to Free Cash Flow -11.3
Growth Rates
Sales Growth Rate 58.5%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate NaN%
Cap. Spend. - 3 Yr. Gr. Rate NaN%
Financial Strength
Quick Ratio 3
Current Ratio 0
LT Debt to Equity -944.4%
Total Debt to Equity -1288.9%
Interest Coverage -3
Management Effectiveness
Return On Assets -39.3%
Ret/ On Assets - 3 Yr. Avg. -40.3%
Return On Total Capital -74.8%
Ret/ On T. Cap. - 3 Yr. Avg. -63.4%
Return On Equity 125.5%
Return On Equity - 3 Yr. Avg. 107.9%
Asset Turnover 0.8
Profitability Ratios
Gross Margin 73.8%
Gross Margin - 3 Yr. Avg. 67.6%
EBITDA Margin -44.6%
EBITDA Margin - 3 Yr. Avg. -86.8%
Operating Margin -50.8%
Oper. Margin - 3 Yr. Avg. -92.2%
Pre-Tax Margin -58.5%
Pre-Tax Margin - 3 Yr. Avg. -103.9%
Net Profit Margin -66.2%
Net Profit Margin - 3 Yr. Avg. -103.4%
Effective Tax Rate -13.2%
Eff/ Tax Rate - 3 Yr. Avg. -1.8%
Payout Ratio 0%

AMRN stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the AMRN stock intrinsic value calculation we used $181 million for the last fiscal year's total revenue generated by Amarin ADR. The default revenue input number comes from 2017 income statement of Amarin ADR. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our AMRN stock valuation model: a) initial revenue growth rate of 39.2% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 13.5%, whose default value for AMRN is calculated based on our internal credit rating of Amarin ADR, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Amarin ADR.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of AMRN stock the variable cost ratio is equal to 60.7%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $120 million in the base year in the intrinsic value calculation for AMRN stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 8.2% for Amarin ADR.

Corporate tax rate of 27% is the nominal tax rate for Amarin ADR. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the AMRN stock is equal to 7.7%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for AMRN are equal to 4.7%.

Life of production assets of 10 years is the average useful life of capital assets used in Amarin ADR operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for AMRN is equal to 2.8%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $-65 million for Amarin ADR - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 271 million for Amarin ADR is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Amarin ADR at the current share price and the inputted number of shares is $0.8 billion.

RELATED COMPANIES Price Int.Val. Rating
NEPT Neptune Techno 3.10 27.27  str.buy
TEVA Teva Pharmaceu 24.11 22.62  buy
ABBV AbbVie 98.22 93.18  hold
AZN AstraZeneca AD 37.96 55.39  str.buy
CATB Catabasis Phar 0.650 0.14  str.sell
GSK GlaxoSmithKlin 40.83 39.73  hold
IONS Ionis Pharmace 51.42 128.06  str.buy

COMPANY NEWS

▶ This Small-Cap Biotech Is Poised for Eye-Popping Gains   [Aug-03-18 06:00AM  Motley Fool]
▶ Amarin: 2Q Earnings Snapshot   [Aug-01-18 05:41AM  Associated Press]
▶ 3 Top Biotech Stocks to Buy Right Now   [Jul-13-18 07:31AM  Motley Fool]
▶ Is Now the Perfect Time to Buy Amarin Corporation Stock?   [Jul-11-18 10:00AM  Motley Fool]
▶ Why Amarin Corporation Zoomed 10% Higher Today   [Jun-28-18 05:21PM  Motley Fool]
▶ Amarin: 1Q Earnings Snapshot   [May-02-18 05:52AM  Associated Press]
▶ 3 Stocks That Could Put Tesla's Returns to Shame   [May-01-18 06:02AM  Motley Fool]
▶ Boom-or-Bust News Is On Tap Soon for Amarin   [Apr-04-18 07:16PM  Motley Fool]
▶ 7 Stocks for the Biotech Takeover Wave   [06:00AM  Investopedia]
▶ Amarin Commemorates National Triglycerides Day on March 28   [Mar-27-18 04:30PM  GlobeNewswire]
▶ Amarin Announces First Middle East Approval for Vascepa®   [Mar-21-18 05:00AM  GlobeNewswire]
▶ 3 Stocks That Could Put Alibaba's Returns to Shame   [Mar-20-18 08:46AM  Motley Fool]
▶ Amarin reports 4Q loss   [Feb-27-18 05:41AM  Associated Press]
▶ Amarin Prices Public Offering of American Depositary Shares   [Jan-30-18 08:58AM  GlobeNewswire]
▶ Heres Whats Moving Amarin Corporation and Puma Biotechnology   [Jan-24-18 09:09AM  Market Exclusive]
▶ Why Amarin Corporation Stock Is Surging Today   [Jan-23-18 12:13PM  Motley Fool]
▶ 3 Growth Stocks to Own in 2018   [10:00AM  Motley Fool]
▶ ETFs with exposure to Amarin Corp. Plc : November 6, 2017   [Nov-06-17 11:03AM  Capital Cube]
▶ Amarin reports 3Q loss   [06:29AM  Associated Press]
▶ ETFs with exposure to Amarin Corp. Plc : October 23, 2017   [Oct-23-17 10:19AM  Capital Cube]
▶ ETFs with exposure to Amarin Corp. Plc : October 10, 2017   [Oct-10-17 10:58AM  Capital Cube]
▶ Amarin to Present at Cantor Global Healthcare Conference   [Sep-20-17 04:30PM  GlobeNewswire]
▶ ETFs with exposure to Amarin Corp. Plc : August 31, 2017   [Aug-31-17 05:12PM  Capital Cube]
Follow us on:   twitter   twitter   twitter   twitter

ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.